SCHEMBL8920256

SCHEMBL8920256

O=C1CCC(c2cccc(Cl)c2)c2ccccc2N1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.54
DDB1 Q16531 5/20 0.47
CRBN Q96SW2 5/20 0.47
TP53 P04637 3/20 0.46
MDM2 Q00987 1/20 0.46
MAPT P10636 3/20 0.44
GAA P10253 1/20 0.44
SLC6A3 Q01959 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
CASP1 P29466 1/20 0.41
CYP2C19 P33261 1/20 0.41
RECQL P46063 1/20 0.41
SLC8B1 Q6J4K2 1/20 0.41
ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL880264 0.86 LMNA (0.67) LMNATP53MAPTGAASLC6A3
SCHEMBL30005837 0.86 LMNA (0.67) LMNATP53MAPTGAASLC6A3
SCHEMBL8922504 0.85 DDB1 (0.50) DDB1CRBNTP53MDM2MAPT
SCHEMBL3053841 0.84 DDB1 (0.65) DDB1CRBNMAPTTSHR
SCHEMBL8922817 0.84 SLC6A2 (0.51) LMNADDB1CRBNTP53MAPT
SCHEMBL8922488 0.82 DDB1 (0.55) LMNADDB1CRBNTP53MDM2
SCHEMBL8708396 0.81 DDB1 (0.68) LMNADDB1CRBNTP53MDM2
SCHEMBL8921450 0.79 LMNA (0.44) LMNAMAPTGAASLC6A3
SCHEMBL8102823 0.79 DDB1 (0.48) DDB1CRBNTP53MAPTGAA
SCHEMBL8920781 0.76 CRBN (0.52) DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663523-B2 BET protein-inhibiting 5-aryltriazoleazepines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-05-30 US disclosed
EP-2900672-B1 BET-PROTEIN INHIBITORY 5-ARYL-TRIAZOLO-AZEPINES Bayer Pharma AG (DE) 2017-02-22 EP disclosed
US-20150299201-A1 BET PROTEIN-INHIBITING 5-ARYL TRIAZOLE AZEPINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-10-22 US disclosed
EP-2900672-A1 BET PROTEIN-INHIBITING 5-ARYL TRIAZOLE AZEPINES Bayer Pharma Aktiengesellschaft (DE) 2015-08-05 EP disclosed
US-5643904-A Substituted hexahdryoazepinones and tetrahydrobenzazepinones PFIZER INC. (US) 1997-07-01 US disclosed
US-5484917-A FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL DISORDERS, PAIN AND ANXIETY PFIZER INC. (US) 1996-01-16 US disclosed
WO-1993015059-A1 3-PHENYLUREIDO-AZEPIN-2-ONES AND -BENZAZEPIN-2-ONES USEFUL AS CHOLECYSTOKININ ANTAGONISTS PFIZER INC. (US) 1993-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299201-A1 BET PROTEIN-INHIBITING 5-ARYL TRIAZOLE AZEPINES BRD4, BRDT, BET1 LMNA 2586/4885DDB1 323/4885CRBN 585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.